Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu

Journal of Immunology

Volumn 173, Issue 1, 2004, Pages 394-401

  Riemer, Angelika B ^a   Klinger, Markus ^a   Wagner, Stefan ^a   Bernhaus, Astrid ^a   Mazzucchelli, Luca ^c   Pehamberger, Hubert ^a,b   Scheiner, Otto ^a   Zielinski, Christoph C ^a   Jensen Jarolim, Erika ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MIMOTOPE; PEPTIDE; RITUXIMAB; TETANUS TOXOID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; ENDOSOME; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERNATIONAL COOPERATION; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; MOUSE; MOUSE STRAIN; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL;

EID: 2942741136     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.1.394     Document Type: Article

References (49)

1. Stern, D. F., P. A. Heffeman, and R. A. Weinberg. 1986. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol. 6:1729.
2. Press, M. F., C. Cordon-Cardo, and D. J. Slamon. 1990. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953.
3. Yarden, Y. 2001: Biology of HER2 and its importance in breast cancer. Oncology 61:1.
4. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707.
5. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165.
6. Rongcun, Y., F. Salazar-Onfray, J. Charo, K. J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. 1999. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163:1037.
7. Brossart, P., G. Stuhler, T. Flad, S. Stevanovic, H. G. Rammensee, L. Kanz, and W. Brugger. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732.
8. Chow, N. H., H. S. Liu, H. B. Yang, S. H. Chan, and I. J. Su. 1997. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma: an immunohistochemical study. Virchows Arch. 430:461.
9. Tzahar, E., and Y. Yarden. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377:M25.
10. Pupa, S. M., S. Menard, S. Andreola, and M. I. Colnaghi. 1993. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res. 53:5864.
11. Disis, M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R. B. Livingston, et al. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
12. Fisk, B., J. M. Hudson, J. Kavanagh, J. T. Wharton, J. L. Murray, C. G. Ioannides, and A. P. Kudelka. 1997. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res. 17:45.
13. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387.
14. Harwerth, I. M., W. Wels, J. Schlegel, M. Muller, and N. E. Hynes. 1993. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68:1140.
15. Hurwitz, E., I. Stancovski, M. Sela, and Y. Yarden. 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA 92:3353.
16. Yip, Y. L., G. Smith, J. Koch, S. Dubel, and R. L. Ward. 2001. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 166:5271.
17. Yip, Y. L., and R. L. Ward. 2002. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol. Immunother. 50:569.
18. Vaisman, N., A. Nissim, L. N. Klapper, B. Tirosh, Y. Yarden, and M. Sela. 2000. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol. Lett. 75:61.
19. Klapper, L. N., M. H. Kirschbaum, M. Sela, and Y. Yarden. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77:25.
20. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639.
21. Vogel, C., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2001. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37(Suppl. 1):S25.
22. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:719.
23. Pegram, M. D., A. Lipton, D. F. Hayes, B. L. Weber, J. M. Baselga, D. Tripathy, D. Baly, S. A. Baughman, T. Twaddell, J. A. Glaspy, and D. J. Slamon. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:2659.
24. +/MCB) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol. 17:98 (Abstr. 377).
25. Burstein, H. J., I. Kuter, S. M. Campos, R. S. Gelman, L. Tribou, L. M. Parker, J. Manola, J. Younger, U. Matulonis, C. A. Bunnell, et al. 2001. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19:2722.
26. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783.
27. O'Shaughnessy, J., S. J. Vukelja, T. Marsland, G. Kimmel, S. Ratnam, and J. Pippen. 2002. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin. Breast. Cancer 3(Suppl. 1):17.
28. Prchla, E., E. Kuechler, D. Blaas, and R. Fuchs. 1994. Uncoating of human rhinovirus serotype 2 from late endosomes. J. Virol. 68:3713.
29. Klinger, M., O. Kudlacek, M. G. Seidel, M. Freissmuth, and V. Sexl. 2002. MAP kinase stimulation by CAMP does not require RAP1 but SRC family kinases. J. Biol. Chem. 277:32490.
30. Mazzucchelli, L., J. B. Burritt, A. J. Jesaitis, A. Nusrat, T. W. Liang, A. T. Gewirtz, F. J. Schnell, and C. A. Parkos. 1999. Cell-specific peptide binding by human neutrophils. Blood 93:1738.
31. Parmley, S. F., and G. P. Smith. 1988. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305.
32. Barbas, III, C. F., A. S. Kang, R. A. Lerner, and S. J. Benkovic. 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88:7978.
33. Wouters, F. S., and P. I. Bastiaens. 1999. Fluorescence lifetime imaging of receptor tyrosine kinase activity in cells. Curr. Biol. 9:1127.
34. Cho, H. S., K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, D. W. Denney, Jr., and D. J. Leahy. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756.
35. Esserman, L. J., T. Lopez, R. Montes, L. N. Bald, B. M. Fendly, and M. J. Campbell. 1999, Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47:337.
36. Disis, M. L., J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin, and M. A. Cheever. 1996. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J. Immunol. 156:3151.
37. Disis, M. L., K. H. Grabstein, P. R. Sleath, and M. A. Cheever. 1999. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1289.
38. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20:2624.
39. Concetti, A., A. Amici, C. Petrelli, A. Tibaldi, M. Provinciali, and F. M. Venanzi. 1996. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol. Immunother. 43:307.
40. Disis, M. L., S. M. Pupa, J. R. Gralow, R. Dirtadi, S. Menard, and M. A. Cheever. 1997. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15:3363.
41. Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams, G. O. Lovrecz, H. J. Zhu, F. Walker, M. J. Frenkel, P. A. Hoyne, et al. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110:763.
42. Dakappagari, N. K., D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. Kaumaya. 2000. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60:3782.
43. Felici, F., A. Luzzago, A. Folgori, and R. Cortese. 1993. Mimicking of discontinuous epitopes by phage-displayed pepfides II: selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 128:21.
44. Hoess, R., U. Brinkmann, T. Handel, and I. Pastan. 1993. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 128:43.
45. Geysen, H. M., S. J. Rodda, and T. J. Mason. 1986. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol. Immunol. 23:709.
46. Jensen-Jarolim, E., A. Leitner, H. Kalchhauser, A. Zurcher, E. Ganglberger, B. Bohle, O. Scheiner, G. Boltz-nitulescu, and H. Breiteneder. 1998. Peptide mimotopes displayed by phage inhibit antibody binding to bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. 12:1635.
47. Hafner, C., U. Samwald, S. Wagner, F. Felici, E. Heere-Ress, E. Jensen-Jarolim, K. Wolff, O. Scheiner, H. Pehamberger, and H. Breiteneder. 2002. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J. Invest. Dermatol. 119:865.
48. Riemer, A., B. Hantusch, G. Kraml, B. Sponer, C. Hafner, H. Breiteneder, C. Zielinski, O. Scheiner, E. Jensen-Jarolim, and H. Pehamberger. 2002. Mimotopes for high molecular weight, melanoma-associated antigen fused to albumin binding protein elicit anti-melanoma antibodies in BALB/c mice. Eur. J. Cancer. 38:S139.
49. Seidman, A., C. Hudis, M. K. Pierri, S. Shak, V. Paton, M. Ashby, M. Murphy, S. J. Stewart, and D. Keefe. 2002. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20:1215.